Login to Your Account

Triggers $50M Milestone Payment

Sucampo's Amitiza Gets FDA Nod in IBS with Constipation

By Jennifer Boggs

Thursday, May 1, 2008
The FDA approved Sucampo Pharmaceuticals Inc.'s Amitiza (lubiprostone) for female patients with constipation-predominant irritable bowel syndrome (IBS-C), making it the only U.S.-approved drug for that indication following the marketing suspension of Novartis AG's Zelnorm last year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription